Sai Life Sciences Ltd

Sai Life Sciences Limited's investor presentation for Q2 FY27 highlights strong financial performance, with revenue growing 23% year-on-year to ₹659 crore and EBITDA margins at 28%. The company reported a 19% YoY increase in PAT to ₹172 crore for the half-year, with CDMO contributing 62% of revenue. Management emphasized progress in integrated outsourcing models, strategic customer relationships, and capacity expansion, with ₹621 crore invested in H1 FY27. Operational updates include the commencement of an end-to-end integrated collaboration, expansion of strategic engagements, and sustainability achievements like Zero Waste to Landfill Platinum certification. The presentation also outlines the company's global presence, R&D capabilities, and digital transformation initiatives. Financial highlights show consistent revenue growth across CRO and CDMO segments, with a focus on new modalities like peptides and ADCs. The company maintains a strong regulatory track record and has received certifications such as Great Place To Work and EcoVadis Platinum for sustainability.

The presentation emphasizes strong financial performance, operational progress, and strategic growth initiatives.